BiomX Inc. has presented a corporate update highlighting its clinical-stage programs aimed at addressing the pressing issue of antibiotic resistance. The company focuses on phage therapy, a promising approach for treating persistent infections. Key developments include positive Phase 2 data for BX211 in treating _S. aureus_ infections, demonstrating sustained ulcer reduction and superior recovery outcomes in bone-depth ulcers. Additionally, BX004 has shown positive Phase 1b/2a results in cystic fibrosis patients with _P. aeruginosa_ infections, indicating sputum culture conversion, improved lung function, and bacterial reduction, with an ongoing Phase 2b study. You can access the full presentation through the link below.